Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line - a Non-interventional Study on the Assessment of Deep Molecular Response in CML Patients in Daily Routine.

NCT05734053 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05734053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05734053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line - a Non-interventional Study on the Assessment of Deep Molecular Response in CML Patients in Daily Routine.
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
June 28, 2016
Completion date
September 8, 2022
Enrollment
222 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia